Apellis Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview

Apellis Pharmaceuticals

05/05/2025 13:50

Apellis Pharmaceuticals Inc APLS.OQ APLS.O is expected to show a rise in quarterly revenue when it reports  results on May 7 for the period ending March 31 2025

The Waltham Massachusetts-based  company is expected to report a 14.0% increase in revenue to $196.485 million from $172.33 million a year ago, according to the mean estimate from 21 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Apellis Pharmaceuticals Inc is for a loss of 35 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.7% in the last three months. ​

Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $41.50​, above​ its last closing price of $20.34. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.39
-0.39
-0.29
Beat
24.8
Sep. 30 2024
-0.30
-0.30
-0.46
Missed
-53.3
Jun. 30 2024
-0.30
-0.32
-0.28
Beat
13.5​
Mar. 31 2024
-0.50
-0.47
-0.42
Beat
10
​​Dec. 31 2023
-0.67
-0.69
-0.73
Missed
-6.4
Sep. 30 2023
-0.80
-0.86
-1.17
Missed
-36.8​
Jun. 30 2023
-1.32
-1.32
-1.02
Beat
22.9
Mar. 31 2023
-1.50
-1.46
-1.56
Missed
-6.5

This summary was machine generated May 5 at 12:50 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)